Core Insights - A new antibiotic, pre-methenamine C lactone, has been discovered by chemists from the University of Warwick and Monash University, showing over 100 times higher antibacterial activity against various resistant pathogens compared to the known antibiotic methenamine A [1][2] - The discovery was made during the synthesis of methenamine A, where previously untested intermediates exhibited significant antibacterial properties, particularly against MRSA and VRE [1] Group 1 - The new antibiotic demonstrates significant efficacy against MRSA, a superbug resistant to multiple common antibiotics, and VRE, which can resist the strongest antibiotic vancomycin [1] - Pre-methenamine C lactone showed no signs of resistance in enterococci during experiments, unlike vancomycin, which induced resistance under the same conditions [1] - The findings suggest that pre-methenamine C lactone could be a potential new candidate drug for combating VRE infections [1] Group 2 - Pre-methenamine C lactone is characterized by its simple structure, strong activity, low likelihood of developing resistance, and ease of synthesis, positioning it as a promising candidate for a new generation of antibiotics [2] - This discovery offers hope to the approximately 1.1 million people who lose their lives each year due to antibiotic resistance [2]

Core Insights - Pfizer's new antibacterial drug, Sifonuo® (injection of amikacin and avibactam), has been officially approved by the National Medical Products Administration for treating complex intra-abdominal infections (cIAI) and hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP) caused by Gram-negative bacteria [1][2] Group 1 - Sifonuo® is the first β-lactam/β-lactamase inhibitor combination that covers all enzyme types of carbapenem-resistant Enterobacteriaceae (CRE), effectively targeting KPC and OXA-48 carbapenemases, and addressing the issue of MBL-producing bacteria [1] - The drug's broad-spectrum enzyme inhibition activity not only improves patient treatment outcomes but also reduces the risk of antibiotic resistance [1] - The approval of Sifonuo® is significant for public health and innovative treatment paradigms, as it helps combat the trend of bacterial resistance and enhances precise coverage against CRE infections [1] Group 2 - Pfizer's China President, Jean-Christophe Pointeau, emphasized the global challenge of antibiotic resistance and the company's commitment to developing innovative anti-infective drugs to address resistant bacterial infections [2] - The approval of Sifonuo® expands the treatment options for carbapenem-resistant Gram-negative bacteria (CRO) and provides innovative solutions for targeted therapy, benefiting more patients [2] - Pfizer expresses gratitude to the National Medical Products Administration and other relevant departments for their support of new antibacterial drugs, reaffirming its mission to bring breakthrough innovations that change patients' lives [2]